BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 45,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 45,000 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00. Following the sale, the chief executive officer directly owned 643,209 shares in the company, valued at $62,346,248.37. The trade was a 6.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Price Performance

Shares of BioNTech stock traded up $2.13 on Monday, reaching $98.86. The stock had a trading volume of 1,212,282 shares, compared to its average volume of 1,111,191. The business’s 50 day moving average is $96.98 and its two-hundred day moving average is $95.27. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a market cap of $25.00 billion, a P/E ratio of -12.63 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech’s revenue was down 59.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.60) EPS. As a group, research analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently added to or reduced their stakes in BNTX. Larson Financial Group LLC increased its position in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in BioNTech in the 2nd quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd boosted its stake in BioNTech by 1,012.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after buying an additional 506 shares in the last quarter. Vestcor Inc purchased a new stake in BioNTech in the fourth quarter worth approximately $153,000. Finally, Rockefeller Capital Management L.P. grew its position in BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after acquiring an additional 1,423 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on BNTX. Canaccord Genuity Group decreased their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $117.00 to $135.00 in a research note on Wednesday, May 27th. BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $128.00 to $105.00 in a report on Tuesday, September 8th. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Citigroup decreased their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.